




**Suppl. Material to Nencioni et al. “Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice” (Thromb Haemost 2014; 111.2)**




**Suppl. Figure 1: FK866 treatment does not affect percentages of circulating neutrophils and monocytes in hypercholesterolaemic mice.** A) Circulating neutrophil percentages in FK866 and Vehicle-treated hypercholesterolaemic mice. Neutrophils were quantified as CD45+CD11b+Ly6G+CD115- cells. B) Circulating monocyte percentages in FK866 and Vehicle-treated hypercholesterolaemic mice. Monocytes were quantified as CD45+CD11b+Ly6G-CD115+ cells. Data are expressed as mean±SEM (n=5-6), N.S.= not significant.





**Suppl. Figure 2: Pre-treatment with FK866 does not affect *in vitro* TNF-alpha-induced neutrophil degranulation.** MPO (A), MMP-8 (B) and MMP-9 (C) release in supernatants of neutrophils pre-incubated with different concentrations of FK866 and then stimulated in polystyrene dishes in the presence or absence of control medium (CTL), 10 ng/ml phorbol-12-myristate-13-acetate (PMA, positive control), or 100 ng/ml TNF-alpha. Data are expressed as median (interquartile range) (n=8).




**Suppl. Figure 3: Pre-treatment with FK866 does not affect pro-MMP-9 activity in supernatants of TNF-alpha-stimulated neutrophils.** A) Representative gel of MMP-9 zymography and results of densitometric quantifications of 8 different experiments performed in polystyrene dishes. White band (arrow) on the gel represents the pro-MMP-9 gelatinolytic activity of standard recombinant pro-MMP-9 (ST), and supernatants of cells treated with control medium (CTL) FK866 alone, 10 ng/ml PMA (positive control) and increasing concentrations of FK866 and concomitant presence of 100 ng/ml TNF-alpha. B) Densitometry of pro-MMP-9 gels. Data are expressed as median (interquartile range) (n=8).




**Suppl. Figure 4: Pre-treatment with FK866 does not affect *in vitro* PMA-induced neutrophil degranulation.** MPO (A), MMP-8 (B) and MMP-9 (C) release in supernatants of neutrophils pre-incubated with different concentrations of FK866 and then stimulated in polystyrene dishes in the presence or absence of control medium (CTL) or 10 ng/ml PMA. D. Representative gel of MMP-9 zymography and results of densitometric quantifications of 8 different experiments performed in polystyrene dishes. White band (arrow) on the gel represents the pro-MMP-9 gelatinolytic activity of standard recombinant pro-MMP-9 (ST), and supernatants of cells treated with control medium (CTL) FK866 alone, 10 ng/ml PMA alone and with increasing concentrations of FK866. E. Densitometry of pro-MMP-9 gels. Data are expressed as median (interquartile range) (n=8).

**A****B**

**Suppl. Figure 5: NAMPT is expressed in HECV cells.** HECV cells were incubated for 48 h with control vehicle or FK866 at the indicated concentrations. Thereafter, cells were used for cytosolic extract preparation and NAMPT and β-actin levels were quantified by immunoblotting. A) One representative experiment out of three is presented. Lower panel, Densitometry of the immunoblotting. B) Intracellular NAD<sup>+</sup> determination in endothelial cells incubated in the presence of absence of FK866 (10 nM).



**Suppl. Figure 6: FK866 treatment does not affect *in vitro* endothelial cell viability.** A) Analysis of apoptosis rate in cultured human endothelial cells in the presence of vehicle (1% DMSO) or FK866 (10 nM) for 48h. Results were expressed as mean±SD (n=3 per group). B) Representative panel of flow cytometric analysis of annexin V/PI staining of vehicle- or FK866 treated cells at 48h of incubation.



**Suppl. Figure 7: FK866 treatment does not affect *in vivo* intraplaque apoptosis.** A) Quantification of apoptotic intraplaque areas in Vehicle- and FK866-treated animals. Data are expressed as mean $\pm$ SEM (n=3-5 per group). B) Representative microphotographs of cryosections from aortic roots of Vehicle- and FK866-treated mice stained for TUNEL (apoptotic cells). On the right panel, higher magnification (20X) images showing intraplaque apoptotic areas are shown.